News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1.  New Data Show Truxima (CT-P10) to Have Comparable Efficacy and Tolera

 New Data Show Truxima (CT-P10) to Have Comparable Efficacy and Tolerability in Advanced Follicular Lymphoma to Reference i.v. Rituximab14/06/2017• Results of a randomized controlled trial to assess the efficacy and tolerability of Truxima® (i.v. rituximab) in patients with advanced follicular lymphoma (AFL) add to the growing bank of published clinical evidence for comparability to the reference product1-4• This is the first presentation of clinical efficacy data in AFL fo


2. Evotec Joins NURTuRE Consortium to Mine Unique Kidney Disease Patient

Evotec Joins NURTuRE Consortium to Mine Unique Kidney Disease Patient Biobank14/06/2017> National Unified Renal Translational Research Enterprise ("NURTuRE") enables Evotec to perform drug discovery based on unique kidney disease patient cohorts> NURTuRE consists of UK-based academic institutions coordinated by Kidney Research UK and selected industry partners> NURTuRE is accessing thousands of kidney patient derived samples and data sets to characterise human pathology with detailed hi


3. »Lab282« Accelerates with Second Round Funding

»Lab282« Accelerates with Second Round Funding20/06/2017The drug discovery partnership between Oxford University, Evotec and Oxford Sciences Innovation Awards five new life sciences projectsEvotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that LAB282, the drug discovery BRIDGE between Oxford University, has made its second round of awards to support promising life sciences ideas emerging from the University.LAB282 is providing critical early stage g


4. Oxford Immunotec Names Karen Koski Head of Strategy and Investor Relat

Oxford Immunotec Names Karen Koski Head of Strategy and Investor Relations05/06/2017OXFORD, United Kingdom and MARLBOROUGH, Mass., June 5, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the appointment of Karen Koski as Head of Strategy and Investor Relations. The newly created position will repor


5. Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at t

Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS Congress23/06/2017Summit Therapeutics plc('Summit', or 'the Company')SUMMIT PRESENTS DATA FROM PHASE 1 CLINICAL PROGRAMME OF EZUTROMID AT THE EUROPEAN PAEDIATRIC NEUROLOGY SOCIETY CONGRESSSummit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, today announces the presentation



Page 26 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2018